Skip to main content

Intensity Therapeutics, Inc.

corporate_fare Company Profile

Intensity Therapeutics, Inc.

INTS·NASDAQ·Life Sciences·CIK 0001567264

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on localized cancer reduction and anti-cancer immune activation. The company develops a unique product from its DfuseRx SM discovery platform, which involves direct injection into tumors. This intratumoral (IT) treatment aims to contain drugs within a tumor without systemic spread. The company addresses the challenge that a tumor's microenvironment, characterized by its stromal, high-fat, dense, poorly vascularized, and pressurized nature, does not absorb water-based products. Intensity Therapeutics believes this drug delivery challenge limits the effectiveness of prior IT treatments. The company has developed a product candidate designed to overcome this local delivery challenge within the tumor. Evidence suggests the mechanism of tumor killing achieved by its drug candidate also leads to systemic immune activation and T-cell repertoire expansion in certain cancers. The DfuseRx SM platform creates patented anti-cancer product candidates composed of active anti-cancer agents and amphiphilic molecules. Amphiphilic molecules have components soluble in both water and fat/oils. When mixed with therapeutic agents, these agents also become soluble in both fat and water. The company's product candidates are novel formulations combining potent anti-cancer drugs with these amphiphilic agents.

Intensity Therapeutics, Inc. (NASDAQ:INTS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for INTS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for INTS spans 10-Q, 8-K, 10-K, 424B5.

Recent high-impact activity:

  • Q3 Loss Widens to $3.5M as Cash Drops to $8.5M; Two Trials Resume Enrollment
  • Intensity Therapeutics Q3 2026: Cash Falls to $8.5M, Going-Concern Doubt Persists
  • Intensity Therapeutics Restarts Key Cancer Trials, Cash at $9.5M
  • Intensity Therapeutics Q2 2026: Cash Drops to $9.5M, Going Concern Warning Reiterated, Clinical Trials Resume
  • Stockholders Approve 6.6% Potential Dilution for Incentive Plans

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$11.61M
Diluted EPS
-$8.56
Op. Cash Flow
-$9.23M
Operating Income
-$11.97M
Cash & Equivalents
$11.92M
Debt / Equity
0.00×
Shares Outstanding
2.52M sh
Source: 10-K · filed 2026-03-27 · accession 0001567264-26-000024

Short Interest & Short Volume

7.24 days to cover

FINRA reported short interest of 75,853 shares in INTS as of the October 30, 2026 settlement, a 13.6% decrease from the prior period — about 7.2 days to cover at its recent average daily volume. On November 20, 2026, 28.7% of INTS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)75,853 shares as of October 30, 2026
Change vs prior period▼ 13.6%
Days to cover7.24 at avg daily volume of 10,470
Daily short volume (FINRA facilities)28.7% of 25,643 shares on November 20, 2026
5-day average short volume37.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for INTS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-16.

Increased Share Authorization · Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with I →
$2.43 -2.02% today
52-week range · as of 2026-11-05 $2.43 – $15.75
Market cap
$8.19M
Volume
62.4K (2.9× avg)
3-mo avg 21.2K
Live data · 2026-11-21 06:22 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed INTS - Latest Insights

INTS
Nov 05, 2026, 7:45 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $2.43 info
Change: -$0.820 (-25%) info
Market Cap: $8.187M info
INTS
Nov 05, 2026, 7:39 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.25
Real-time Price: $2.43 info
Change: -$0.820 (-25%) info
Market Cap: $8.187M info
INTS
Aug 11, 2026, 7:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $4.19
Real-time Price: $2.43 info
Change: -$1.76 (-42%) info
Market Cap: $8.187M info
INTS
Aug 11, 2026, 7:17 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.19
Real-time Price: $2.43 info
Change: -$1.76 (-42%) info
Market Cap: $8.187M info
INTS
Jun 16, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $2.43 info
Change: -$1.28 (-35%) info
Market Cap: $8.187M info
INTS
May 07, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $2.43 info
Change: -$2.68 (-52%) info
Market Cap: $8.187M info
INTS
May 07, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $2.43 info
Change: -$2.68 (-52%) info
Market Cap: $8.187M info
INTS
Mar 27, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.95
Real-time Price: $2.43 info
Change: -$3.52 (-59%) info
Market Cap: $8.187M info
INTS
Mar 27, 2026, 4:01 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $6.03
Real-time Price: $2.43 info
Change: -$3.60 (-60%) info
Market Cap: $8.187M info
INTS
Mar 23, 2026, 4:00 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $6.22
Real-time Price: $2.43 info
Change: -$3.79 (-61%) info
Market Cap: $8.187M info
INTS
Mar 06, 2026, 8:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.95
Real-time Price: $2.43 info
Change: -$5.52 (-69%) info
Market Cap: $8.187M info
INTS
Mar 06, 2026, 7:48 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.78
Real-time Price: $2.43 info
Change: -$5.35 (-69%) info
Market Cap: $8.187M info
INTS
Mar 05, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.69
Real-time Price: $2.43 info
Change: -$5.26 (-68%) info
Market Cap: $8.187M info
INTS
Feb 13, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2502
Real-time Price: $2.43 info
Change: Reverse Stock Split info
Market Cap: $8.187M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets